Sirolimus Eluting Coronary Stent System
World's Longest Studied Drug Eluting Stent
New generation DES providing synergy of Biodegradable Polymer with microporous surface to enhance optimal performance.
Optimal Drug Release
- Microporous Surface- Small pores on the stent surface ensures optimum drug release with minimal use of polymer.
- Shellac Resin (Wax-free) ensures better polymer-drug binding with negligible polymer flaking during stent expansion.
Better Endothelialisation & Superior Strut Coverage
- Abluminal Coating- Drug polymer matrix coated only on the abluminal side for drug release only to target tissue.
- No polymer on the luminal side ensures healthy endothelialization
Clinical Studies
In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.
Comparison of clinical outcomes at 10 years in patients treated with new-generation BP-SES versus new-generation PP-EES versus early generation SES.
*As per Clinical data with SS stent using similar microporous surface and drug coating technology
